Literature DB >> 12482331

Pathologic prognostic factors in the recurrence of rectal cancer.

Carolyn C Compton1.   

Abstract

For rectal cancer, local recurrence following surgical treatment is a grave complication that occurs in as many as 25% of cases. Pathological examination of the surgical resection specimen plays a primary role in assessing both the surgery- and tumor-related factors that contribute to the risk of recurrence. Among the tumor-related factors, stage has long been considered the single most accurate indicator of survival. However, recent evidence strongly suggests that the most powerful predictor of both local recurrence and overall outcome in the absence of distant metastatic disease is the macroscopic quality of the mesorectum in the resection specimen and the proximity of the tumor to the circumferential (radial) resection margin. Additional pathologic features have been shown to have stage-independent prognostic significance in colorectal cancer and may help to further define risk of adverse outcome. Such features include: tumor grade; histologic type; extent of extramural penetration by tumor; neural, venous, and/or lymphatic invasion; tumor border configuration; tumor budding; and host lymphoid response. The predictive value of tumor-specific molecular features is currently under investigation and may help to further improve prognostication and refine individual patient management in rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482331     DOI: 10.3816/CCC.2002.n.020

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  14 in total

1.  [Locally recurrent rectal carcinoma].

Authors:  Th Lehnert; M Golling; J Buchholz
Journal:  Chirurg       Date:  2004-01       Impact factor: 0.955

2.  Quality management in rectal carcinoma: what is feasible?

Authors:  Susanne Merkel; Daniela Klossek; Jonas Göhl; Thomas Papadopoulos; Werner Hohenberger; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2009-06-02       Impact factor: 2.571

3.  Optimised surgery (so-called TME surgery) and high-resolution MRI in the planning of treatment of rectal carcinoma.

Authors:  J Strassburg; A Lewin; K Ludwig; L Kilian; J Linke; V Loy; P Knuth; O Püttcher; U Ruehl; F Stöckmann; M Hackenthal; W Hopfenmüller; A Huppertz
Journal:  Langenbecks Arch Surg       Date:  2007-02-06       Impact factor: 3.445

4.  MRI-detected extramural vascular invasion is an independent prognostic factor for synchronous metastasis in patients with rectal cancer.

Authors:  Beomseok Sohn; Joon-Seok Lim; Honsoul Kim; Sungmin Myoung; Junjeong Choi; Nam Kyu Kim; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2014-12-13       Impact factor: 5.315

Review 5.  [Intra-operative local tumor cell dissemination in rectal carcinoma surgery: effect of operation principles and neoadjuvant therapy].

Authors:  S Merkel; W Hohenberger; P Hermanek
Journal:  Chirurg       Date:  2010-08       Impact factor: 0.955

Review 6.  Tailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer.

Authors:  Melodi J Whitley; Ralph Weissleder; David G Kirsch
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

Review 7.  [Therapy of locally recurrent rectal carcinoma].

Authors:  H G Hempen; H R Raab
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

8.  Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients.

Authors:  Masayoshi Miyoshi; Hideki Ueno; Yojiro Hashiguchi; Hidetaka Mochizuki; Ian C Talbot
Journal:  Ann Surg       Date:  2006-04       Impact factor: 12.969

9.  MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.

Authors:  Amit A Negandhi; Angela Hyde; Elizabeth Dicks; William Pollett; Banfield H Younghusband; Patrick Parfrey; Roger C Green; Sevtap Savas
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 10.  Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  Oncotarget       Date:  2010-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.